Abstracts

MEMRI Reflects HIV-1-Associated Human Pathobiology in a Rodent NeuroAIDS Model

Background: Progressive human immunodeficiency viral (HIV) infection commonly leads to a constellation of cognitive, motor and behavioral impairments. While antiretroviral therapy (ART) reduces disease severity, it does not affect disease prevalence. There are no diagnostic biomarkers for neuroAIDS and co-morbid conditions must first be excluded. To this end, we applied manganese (Mn2+)-enhanced magnetic resonance imaging…

HIV Induces Astrocyte Senescence and Is Reversed by Beta-Catenin Induction

Background: Neuroinflammation and neurodegeneration are hallmarks of HIV-Associated Neurocognitive Disorders (HAND). Astrocyte senescence induces neuropathologies due to increased oxidative stress and altered cytokine secretion leading to neuroinflammation. These processes reduce the neuroprotective capacity of astrocytes leading to long-term inflammation and neurodegeneration. We evaluated the impact of HIV on astrocyte senescence and explored the role of…

HIV-1 Attachment Inhibitor Prodrug BMS-663068: Model-Based Dose Selection

Background: BMS-663068 is a prodrug of BMS-626529, an attachment inhibitor that binds to HIV-1 gp120, preventing initial viral attachment and entry into host CD4+ T-cells. Pharmacokinetic (PK)/pharmacodynamic (PD) modeling of Phase 2 data was performed to guide dose selection for subsequent studies. Methods: PK/PD data from two Phase 2 studies (AI438006, AI438011) in HIV-1-infected subjects…

Tenofovir PK in Adults With Renal Dysfunction on LPV/r and NNRTI-Based ART

Background: The recommended tenofovir disoproxil fumarate (TDF) dose is 300 mg every 48 hours for adults with moderate renal function impairment (creatinine clearance 30-49 mL/min). Coadminsitration of TDF with lopinavir/ritonavir (LPV/r) increases plasma tenofovir (TFV) concentrations in adults with normal renal function. We compared the plasma and intracellular pharmacokinetics (PK) of TDF 300 mg every…

Population Pharmacokinetics of Cotrimoxazole West African HIV-Infected Children

Background: Cotrimoxazole (association of sulfamethoxazole (SMX) and trimethoprim (TMP)) is recommended to prevent opportunistic infections in HIV-infected children. Despite the overwhelming use of this medication, few pharmacokinetics (PK) data are available in children. We investigated the PK of cotrimoxazole in a therapeutic cohort of children initiated < 2 years of age on a combination antiretroviral…

ART Choice Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children

Background: Treatment guidelines for HIV and malaria co-infected children are not developed despite concern that drug interactions impact malaria outcomes. Artemether-lumefantrine (AR-LR), contains long-acting LR with a predominant impact on reinfection rates. Previously, HIV infected children, managed with lopinavir/ritonavir (LPV/r)-based ART, had lower risk for malaria compared to those on efavirenz (EFV) or nevirapine (NVP)-based…